Logo
x

Search

Subscribe Now

vasomotor symptoms

Bayer Initiates P-III OASIS Program of Elinzanetant for the Treatment of Vasomotor Symptoms During Menopause

Bayer Initiates P-III OASIS Program of Elinzanetant for the Treatment of Vasomotor Symptoms During Menopause

  • September 1, 2021
Bayer to Acquire KaNDy Therapeutics for Augmenting its Women's Healthcare Portfolio

Bayer to Acquire KaNDy Therapeutics for Augmenting its Women's Healthcare Portfolio

  • August 11, 2020
Astellas Initiates P-III BRIGHT SKY Clinical Program for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

Astellas Initiates P-III BRIGHT SKY Clinical Program for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

  • August 6, 2019
Astellas to Present P-III (SKYLIGHT 4) Study of Fezolinetant for Vasomotor Symptoms Associated with Menopause at NAMS 2022

    Astellas to Present P-III (SKYLIGHT 4) Study of Fezolinetant for Vasomotor Symptoms Associated with Menopause at NAMS 2022

    • October 13, 2022
    Astellas Reports EMA’s Acceptance of MAA for Fezolinetant to Treat Vasomotor Symptoms Associated with Menopause

      Astellas Reports EMA’s Acceptance of MAA for Fezolinetant to Treat Vasomotor Symptoms Associated with Menopause

      • September 30, 2022
      Astellas Reports P-III (MOONLIGHT 3) Trial Results of Fezolinetant for the Treatment of Vasomotor Symptoms Associated with Menopause

        Astellas Reports P-III (MOONLIGHT 3) Trial Results of Fezolinetant for the Treatment of Vasomotor Symptoms Associated with Menopau...

        • September 5, 2022
        Astellas Reports the Submission of NDA to the US FDA for Fezolinetant to Treat Vasomotor Symptoms Associated with Menopause

          Astellas Reports the Submission of NDA to the US FDA for Fezolinetant to Treat Vasomotor Symptoms Associated with Menopause

          • June 24, 2022
          Astellas Reports 12-Week Results of Fezolinetant in the P-III (MOONLIGHT 1) Trial for the Nonhormonal Treatment of Vasomotor Symptoms in Asia

            Astellas Reports 12-Week Results of Fezolinetant in the P-III (MOONLIGHT 1) Trial for the Nonhormonal Treatment of Vasomotor Sympt...

            • March 15, 2022
            Astellas Reports Results of Fezolinetant in P-III (SKYLIGHT 4) Trial for the Treatment of Vasomotor Symptoms Associated with Menopause

              Astellas Reports Results of Fezolinetant in P-III (SKYLIGHT 4) Trial for the Treatment of Vasomotor Symptoms Associated with Menop...

              • March 8, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.